N-(tert-butyloxycarbonyl)homocycloleucyl-glycine-nitrile | 225122-33-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(tert-butyloxycarbonyl)homocycloleucyl-glycine-nitrile
• 英文别名: Boc-Ac6-GlyCN；Boc-1-amino-cyclohexanecarboxylic acid (1-(cyanomethyl-carbamoyl))-amide；tert-Butyl (1-((cyanomethyl)carbamoyl)cyclohexyl)carbamate；tert-butyl N-[1-(cyanomethylcarbamoyl)cyclohexyl]carbamate
• CAS: 225122-33-8
• 化学式: C₁₄H₂₃N₃O₃
• mdl: MFCD24392169
• 分子量: 281.355
• InChiKey: PSVFZBCOZRVPDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.785
• 拓扑面积：
  91.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(tert-butyloxycarbonyl)homocycloleucyl-glycine-nitrile 在 甲烷磺酸 作用下， 以 四氢呋喃 为溶剂， 以95%的产率得到1-氨基-N-(氰基甲基)环己烷甲酰胺
  参考文献：
  名称：

  探索组织蛋白酶B S2口袋的荧光特性的新型组织蛋白酶抑制剂：设计，合成和生物学评估

  摘要：

  氟还是氟？基于β，β-二氟环脂族氨基酸，新的二肽腈文库被评估为人组织蛋白酶抑制剂。通过分子建模和NMR研究阐明了氟化面相对于组织蛋白酶B蛋白质结构的方向（见图）。对于（R）配置的体，氟原子被定向到S 2凹穴，而在（S）配置的dis体中，氟化面暴露在溶剂中。

  DOI：

  10.1002/chem.201100113
• 作为产物：
  描述：

  1-氨基-1-环己基甲酸 在 三乙胺 、 sodium hydroxide 、 氯甲酸异丁酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 40.08h， 生成 N-(tert-butyloxycarbonyl)homocycloleucyl-glycine-nitrile
  参考文献：
  名称：

  面对酶抑制剂设计中的宝石二烷基效应：基于同环亮氨酸的氮杂肽腈的制备

  摘要：

  一个难以克服的难题：与含有P2亮氨酸残基的氮杂肽腈相比，相应的基于同环亮氨酸的抑制剂的合成更加困难。可能是由于宝石二烷基效应。提出了合成第一个由同环亮氨酸衍生的氮杂二肽腈作为选择性和高效组织蛋白酶K抑制剂的合成途径（参见方案）。

  DOI：

  10.1002/chem.201101350

文献信息

• Dipeptide nitriles
  申请人：Novartis AG

  公开号：US06353017B1

  公开（公告）日：2002-03-05

  N-terminal substituted dipeptide nitriles as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization). Particular dipeptide nitriles are compounds of formula I, or physiologically-acceptable and -cleavable esters or a salts thereof wherein: the symbols are as defined. In particular it has been found that by appropriate choice of groups R, R2, R3, R4, R5, X1, Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.

  N-末端取代二肽腈可作为半胱氨酸蛋白酶抑制剂，例如半胱氨酸蛋白酶B、K、L和S，并可用于治疗依赖于半胱氨酸蛋白酶的疾病和症状，包括炎症、类风湿关节炎、骨关节炎、骨质疏松、肿瘤（尤其是肿瘤侵袭和转移）、冠心病、动脉粥样硬化（包括动脉粥样硬化斑块破裂和不稳定）。特定的二肽腈化合物为公式I的化合物，或其生理上可接受和可裂解的酯或盐，其中：符号如定义。特别是发现通过适当选择基团R、R2、R3、R4、R5、X1、Y和L，可以改变化合物作为各种半胱氨酸蛋白酶类型抑制剂的相对选择性，例如半胱氨酸蛋白酶B、K、L和S，可改变，例如获得选择性抑制特定蛋白酶类型或蛋白酶类型组合的抑制剂。
• Novel compounds and compositions as protease inhibitors
  申请人：AXYS PHARMACEUTICALS, INC.

  公开号：US20020086996A1

  公开（公告）日：2002-07-04

  The present invention relates to novel N-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

  本发明涉及一种新颖的N-氰甲基酰胺，它们是半胱氨酸蛋白酶抑制剂，以及它们的药用盐和N-氧化物，它们作为治疗剂的用途以及它们的制备方法。
• Design and Synthesis of Tri-Ring P₃ Benzamide-Containing Aminonitriles as Potent, Selective, Orally Effective Inhibitors of Cathepsin K
  作者：James T. Palmer、Clifford Bryant、Dan-Xiong Wang、Dana E. Davis、Eduardo L. Setti、Robert M. Rydzewski、Shankar Venkatraman、Zong-Qiang Tian、Leland C. Burrill、Rohan V. Mendonca、Eric Springman、John McCarter、Tobee Chung、Harry Cheung、James W. Janc、Mary McGrath、John R. Somoza、Philip Enriquez、Z. Walter Yu、Robert M. Strickley、Liang Liu、Michael C. Venuti、M. David Percival、Jean-Pierre Falgueyret、Peppi Prasit、Renata Oballa、Denis Riendeau、Robert N. Young、Gregg Wesolowski、Sevgi B. Rodan、Colena Johnson、Donald B. Kimmel、Gideon Rodan

  DOI：10.1021/jm058198r

  日期：2005.12.1

  We have prepared a series of achiral aminoacetonitriles, bearing tri-ring benzamide moieties and an aminocyclohexanecarboxylate residue at P-2. This combination of binding elements resulted in sub-250 pM, reversible, selective, and orally bioavailable cathepsin K inhibitors. Lead compounds displayed single digit nanomolar inhibition in vitro (of rabbit osteoclast-mediated degradation of bovine bone). The best compound in this series, 39n (CRA-013783/ L-006235), was orally bioavailable in rats, with a terminal half-life of over 3 h. 39n was dosed orally in ovariectomized rhesus monkeys once per day for 7 days. Collagen breakdown products were reduced by up to 76% dose-dependently. Plasma concentrations of 39n above the bone resorption IC50 after 24 h indicated a correlation between functional cellular and in vivo assays. Inhibition of collagen breakdown by cathepsin K inhibitors suggests this mechanism of action may be useful in osteoporosis and other indications involving bone resorption.
• N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS
  申请人：AXYS PHARMACEUTICALS, INC.

  公开号：EP1161415B1

  公开（公告）日：2005-07-13
• US6476026B1
  申请人：——

  公开号：US6476026B1

  公开（公告）日：2002-11-05